Asma Dilawari (A Dilawari)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Epidermal Growth Factor Receptor

Drug Administration

Metastatic Breast Cancer

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Breast cancer research and treatment

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Asma Dilawari, James Buturla, Christy Osgood, Xin Gao, Wei Chen, Tiffany K Ricks, Timothy Schaefer, Sreedevi Avasarala, Francisca Reyes Turcu, Anand Pathak, Shyam Kalavar, Vishal Bhatnagar, Justin S Collazo, Nam Atiqur Rahman, Bronwyn D Mixter, Shenghui Tang, Richard Pazdur, Paul Kluetz, Laleh Amiri-Kordestani
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Asma Dilawari, Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H Fiero, Ankit Shah, Salaheldin S Hamed, Junshan Qiu, Jingyu Yu, Wimolnut Manheng, Tiffany K Ricks, Rajan Pragani, Arulvathani Arudchandran, Paresma Patel, Shadia Zaman, Arpita Roy, Shyam Kalavar, Soma Ghosh, William F Pierce, Nam Atiqur Rahman, Shenghui Tang, Bronwyn D Mixter, Paul G Kluetz, Richard Pazdur, Laleh Amiri-Kordestani
FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive, Platinum-Resistant Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Preeti Narayan, Asma Dilawari, Christy Osgood, Zhou Feng, Erik W Bloomquist, William F Pierce, Samina Jafri, Shyam Kalavar, Marina Kondratovich, Prakash Jha, Soma Ghosh, Shenghui Tang, Richard Pazdur, Julia A Beaver, Laleh Amiri-Kordestani
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Elizabeth S Duke, Michael J Fusco, Patrick DeMoss, Asma Dilawari, Gulsum E Pamuk, Jessica Boehmer, Bronwyn D Mixter, Kirsten B Goldberg, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development. Cancer discovery 12 (12) (2022)
Paula R Pohlmann, Deena Graham, Tianmin Wu, Yvonne Ottaviano, Mahsa Mohebtash, Shweta Kurian, Donna McNamara, Filipa C Lynce, Robert Warren, Asma Dilawari, Suman Rao, Candace Mainor, Nicole Swanson, Ming T Tan, Claudine Isaacs, Sandra M Swain
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. Breast cancer research and treatment 196 (3) (2022)
Asma Dilawari, K E Rentscher, W Zhai, X Zhou, T A Ahles, J Ahn, T N Bethea, J E Carroll, H J Cohen, D A Graham, H S L Jim, B McDonald, Z M Nakamura, S K Patel, J C Root, B J Small, A J Saykin, D Tometich, K Van Dyk, J S Mandelblatt, null null
Medical care disruptions during the first six months of the COVID-19 pandemic: the experience of older breast cancer survivors. Breast cancer research and treatment 190 (2) (2021)